Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4686.36% is 86% above its 3-year average of -32935.43%, near the high end of its 3-year range (-1892800.00%–-2060.77%).
1.05% below its 12-month average of -4637.86%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -7394.21%.
EBITDA MARGIN
-4686.36%
EBITDA MARGIN AVG TTM
-4637.86%
EBITDA MARGIN AVG 3Y
-204552.81%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.05%
CURRENT VS 3Y AVG
+97.71%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CG Oncology Inc.
Market Cap
$6.06B
EBITDA Margin
-4686.36%
TTM Avg
-4637.86%
3Y Avg
-204552.81%
5Y Avg
N/A
Market Cap
$6.15B
EBITDA Margin
30.20%
TTM Avg
18.88%
3Y Avg
24.58%
5Y Avg
33.74%
Market Cap
$5.82B
EBITDA Margin
11.63%
TTM Avg
0.63%
3Y Avg
-0.42%
5Y Avg
-80.39%
Market Cap
$6.32B
EBITDA Margin
-139.44%
TTM Avg
-176.89%
3Y Avg
-12100.88%
5Y Avg
-12100.88%
Market Cap
$6.50B
EBITDA Margin
21.42%
TTM Avg
19.40%
3Y Avg
15.87%
5Y Avg
16.39%
Market Cap
$5.53B
EBITDA Margin
-15636.44%
TTM Avg
-8457.23%
3Y Avg
-41454.98%
5Y Avg
-35632.55%
Market Cap
$6.61B
EBITDA Margin
-256.72%
TTM Avg
-936.95%
3Y Avg
-3212.66%
5Y Avg
-4222.05%
Market Cap
$6.62B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$6.68B
EBITDA Margin
15.93%
TTM Avg
16.80%
3Y Avg
17.55%
5Y Avg
18.41%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $6.06B | -4686.36% | -4637.86% | -204552.81% | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.15B | 30.20% | 18.88% | 24.58% | 33.74% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.82B | 11.63% | 0.63% | -0.42% | -80.39% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.32B | -139.44% | -176.89% | -12100.88% | -12100.88% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.50B | 21.42% | 19.40% | 15.87% | 16.39% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.53B | -15636.44% | -8457.23% | -41454.98% | -35632.55% |
| GRAIL Inc. (GRAL)vs › | $6.61B | -256.72% | -936.95% | -3212.66% | -4222.05% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.62B | 6.82% | 6.08% | -0.44% | -8.67% |
| Chemed Corporation (CHE)vs › | $6.68B | 15.93% | 16.80% | 17.55% | 18.41% |
| Doximity, Inc. (DOCS)vs › | $5.35B | 35.56% | 38.69% | 36.58% | 34.55% |
Gross Margin
-15.0%
EBITDA Margin
-4686.4%
Operating Margin
-4722.1%
Net Margin
-3602.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -7394.21% |
| 2026-03-31 | -6052.45% |
| 2025-12-31 | -2060.77% |
| 2025-09-30 | -3044.00% |
| 2025-03-31 | -81115.38% |
| 2024-12-31 | -8344.08% |
| 2024-09-30 | -65753.49% |
| 2024-06-30 | -23284.68% |
| 2024-03-31 | -4246.69% |
| 2023-12-31 | -1892800.00% |
| 2023-09-30 | -155985.19% |
| 2023-03-31 | -5008.76% |
